Rivaroxaban, an oral direct factor Xa inhibitor

Author： Piccini Jonathan P Patel Manesh R Mahaffey Kenneth W Fox Keith AA Califf Robert M

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.6, 2008-06, pp. : 925-937

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rivaroxaban, the first oral, direct factor Xa inhibitor

By Fassiadis Nicholas

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 18, 2009-12 ,pp. : 2945-2946

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor

Current Clinical Pharmacology, Vol. 9, Iss. 1, 2014-02 ,pp. : 75-83

Bentham Science Publishers

Access to resources Recommend Favorite

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - in Patients Undergoing Major Orthopaedic Surgery

By Mueck Wolfgang

Clinical Pharmacokinetics, Vol. 47, Iss. 3, 2008-01 ,pp. : 203-216

Adis International

Access to resources Recommend Favorite

Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty

By Borris Lars C

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 1083-1088

Informa Healthcare

Access to resources Recommend Favorite

Absence of Clinically Relevant Interactions between Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – and Digoxin or Atorvastatin in Healthy Subjects

By Kubitza D Becka M Roth A Mueck W

The Journal of International Medical Research, Vol. 40, Iss. 5, 2012-09 ,pp. : 1688-1707

Field House Publishing

Access to resources Recommend Favorite